NAGLU — Alpha-N-Acetylglucosaminidase

📖 Wiki Page

gene1431 wordssynced 2026-04-02

NAGLU — Alpha-N-Acetylglucosaminidase

Introduction

[NAGLU](/proteins/naglu-protein) (Alpha-N-Acetylglucosaminidase) is a lysosomal enzyme essential for the degradation of [heparan sulfate](/entities/heparan-sulfate) glycosaminoglycans. Mutations in NAGLU cause [mucopolysaccharidosis type IIIB (MPS IIIB)](/diseases/mucopolysaccharidosis-iii), also known as [Sanfilippo syndrome type B](/diseases/sanfilippo-syndrome), a devastating neurodegenerative lysosomal storage disorder. This page provides detailed information about NAGLU's structure, function, and role in disease processes. [@yogalingam2002]

...

NAGLU — Alpha-N-Acetylglucosaminidase

Introduction

<div class="infobox infobox-gene"> [@neufeld2014]
<div class="infobox-header">NAGLU Gene</div> [@aaron1997]
<div class="infobox-row"> [@valstar2008]
<div class="infobox-label">Gene Symbol</div> [@heldermon2007]
<div class="infobox-value">NAGLU</div> [@shapiro2017]
</div> [@sardiello2009]
<div class="infobox-row"> [@cressant2007]
<div class="infobox-label">Full Name</div> [@langfordsmith2014]
<div class="infobox-value">Alpha-N-acetylglucosaminidase</div> [@tardieu2014]
</div> [@matsumoto2023]
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">17q21.2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/4668" target="_blank">4668</a></div>
</div>
<div name="omim-link">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://www.omim.org/entry/609701" target="_blank">609701</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000108784</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/P54802" target="_blank">P54802</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">[Mucopolysaccharidosis IIIB](/diseases/mucopolysaccharidosis-iii), [Sanfilippo Syndrome Type B](/diseases/sanfilippo-syndrome)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Inheritance</div>
<div class="infobox-value">Autosomal Recessive</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Class</div>
<div class="infobox-value">Lysosomal enzyme, Glycosylhydrolase</div>
</div>
</div>

Overview

Mermaid diagram (expand to render)

[NAGLU](/proteins/naglu-protein) encodes alpha-N-acetylglucosaminidase, a lysosomal enzyme that catalyzes the N-acetylglucosaminide hydrolysis in heparan sulfate glycosaminoglycans. It is the third enzyme in the stepwise degradation of [heparan sulfate](/entities/heparan-sulfate), working in concert with [N-sulfoglucosamine sulfohydrolase (SGSH)](/proteins/sgssh-protein) and [heparan N-sulfatase (HGSNAT)](/proteins/hgsnat-protein) to completely break down HS chains [1].

Mutations in NAGLU cause [mucopolysaccharidosis type IIIB (MPS IIIB)](/diseases/mucopolysaccharidosis-iii), also known as [Sanfilippo syndrome type B](/diseases/sanfilippo-syndrome), a neurodegenerative lysosomal storage disorder. The enzyme deficiency leads to accumulation of [heparan sulfate](/entities/heparan-sulfate) in lysosomes throughout the body, particularly affecting the brain and causing progressive neurodegeneration [2].

Function

NAGLU encodes alpha-N-acetylglucosaminidase, a lysosomal enzyme that catalyzes the N-acetylglucosaminide hydrolysis in [heparan sulfate](/entities/heparan-sulfate) glycosaminoglycans. This enzyme is essential for the stepwise degradation of heparan sulfate (HS), a component of the extracellular matrix and cell surface.

Catalytic Mechanism

NAGLU belongs to the family of [glycosylhydrolases](/mechanisms/glycosylation-neurodegeneration) and specifically cleaves the α-N-acetylglucosaminide linkage in HS substrates. The enzyme requires an acidic pH optimum (pH 4.5-5.0) for optimal activity, consistent with the lysosomal environment [3].

Key functions include:

Lysosomal catabolism: Breaks down heparan sulfate in the lysosome
[Autophagy](/mechanisms/autophagy-lysosomal-pathway) regulation: HS accumulation impairs [autophagic flux](/mechanisms/autophagy-lysosomal-pathway)
Neuronal health: Essential for normal neuronal function and survival
Cellular homeostasis: Prevents toxic accumulation of GAGs

Deficiency leads to accumulation of HS in lysosomes, causing cellular toxicity and [neurodegeneration](/diseases/neurodegeneration).

Protein Structure

The NAGLU protein is a homodimer with each subunit approximately 74 kDa. The enzyme contains a signal peptide directing it to the lysosome and a catalytic domain responsible for substrate hydrolysis [3].

Disease Associations

Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B, is caused by autosomal recessive mutations in NAGLU. It is one of four subtypes of Sanfilippo syndrome (MPS IIIA-D), each caused by deficiency of a different enzyme in HS degradation [2][4].

Genotype-Phenotype Correlation

| Mutation Type | Effect | Severity |
|--------------|--------|----------|
| Null mutations | No enzyme activity | Severe, early onset |
| Missense mutations | Reduced activity | Variable severity |
| Late-onset variants | Partial activity | Attenuated phenotype |

Common pathogenic variants:

p.Arg626Trp — most common missense variant
p.Glu401Lys — severe variant
p.Trp398\* — truncating variant
p.Ile490Serfs\*9 — frameshift variant

Pathogenesis

Neurodegeneration in MPS IIIB involves multiple interconnected mechanisms [5][6]:

Lysosomal storage: Accumulation of [heparan sulfate](/entities/heparan-sulfate) in lysosomes leads to cellular swelling and organelle dysfunction

[Autophagy](/mechanisms/autophagy-lysosomal-pathway) impairment: HS accumulation disrupts [autophagic flux](/mechanisms/autophagy-lysosomal-pathway), causing accumulation of damaged mitochondria and protein aggregates

[Neuroinflammation](/mechanisms/neuroinflammation): [Microglial](/cell-types/microglia) activation and chronic neuroinflammation

Synaptic dysfunction: Impaired synaptic transmission and dendritic spine abnormalities

[Oxidative stress](/mechanisms/oxidative-stress-neurodegeneration): Increased [ROS](/entities/reactive-oxygen-species) production and mitochondrial dysfunction

Clinical Features

Progressive cognitive decline
Behavioral problems (hyperactivity, aggression, sleep disturbances)
Motor impairment and ataxia
Speech and language delays
Seizures (in later stages)
Coarse facial features (mild)
Hearing loss

Expression and Regulation

NAGLU is expressed ubiquitously with highest levels in:

Liver and spleen (highest expression)
Brain ([neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes))
Fibroblasts

Enzyme activity is essential in all tissues, but neuronal dysfunction causes the most severe clinical manifestations. Expression is regulated by [lysosomal](/mechanisms/lysosome-dysfunction) stress and [transcription factor EB (TFEB)](/proteins/tfeb), the master regulator of lysosomal biogenesis [7].

Protein Interactions

NAGLU interacts with several proteins in its role in lysosomal heparan sulfate catabolism:

| Partner Protein | Interaction Type | Functional Significance |
|-----------------|------------------|-------------------------|
| [SGSH](/genes/sgsh) | Sequential processing | Works upstream in HS degradation |
| [HGSNAT](/proteins/hgsnat-protein) | Sequential processing | Works upstream in HS degradation |
| [GNS](/proteins/gns-protein) | Sequential processing | Works downstream in HS degradation |
| [GAGNS](/proteins/gagns-protein) | Sequential processing | Works downstream in HS degradation |
| [LAMP1](/proteins/lamp1) | Lysosomal targeting | Mediates lysosomal localization |
| [LAMP2](/proteins/lamp2) | Lysosomal targeting | Mediates lysosomal localization |
| [TFEB](/proteins/tfeb) | Transcriptional regulation | Activates expression under starvation |

Animal Models

Several animal models have been developed to study MPS IIIB [8][9]:

Murine Models

Naglu^-/- mice: Recapitulate key features of human disease including accumulation of HS, neuroinflammation, and behavioral deficits
AAV-mediated gene therapy: Shows promise in crossing the [blood-brain barrier](/mechanisms/bbb-dysfunction-pathway) and delivering functional NAGLU

Phenotypic Characteristics

Progressive accumulation of HS in brain and peripheral tissues
Elevated lysosomal storage in [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes)
Microglial activation and neuroinflammation
Learning and memory deficits
Shorter lifespan compared to wild-type

Therapeutic Implications

Multiple therapeutic strategies are being developed for MPS IIIB [10][11]:

Enzyme Replacement Therapy (ERT)

Recombinant NAGLU administration
Challenges: [Blood-brain barrier](/mechanisms/bbb-dysfunction-pathway) limits CNS delivery

Gene Therapy

AAV vectors (AAV9, AAVrh.10) for CNS delivery
Intrathecal or intravenous administration
Clinical trials ongoing

Substrate Reduction Therapy

Reduce HS biosynthesis to decrease substrate accumulation
Small molecule approaches in development

Chaperone Therapy

Pharmacological chaperones to stabilize mutant enzyme
Best for missense mutations with residual activity

Stem Cell Therapy

Hematopoietic stem cell transplantation
Mesenchymal stem cell approaches

Brain Atlas Resources

Expression data from the [Allen Human Brain Atlas](/allen-human-brain-atlas) shows NAGLU expression across multiple brain regions, with higher expression in [neurons](/cell-types/neurons) compared to [glial cells](/cell-types/astrocytes). Single-cell data indicates variable expression in different [neuronal subtypes](/cell-types/cortical-pyramidal-neurons).

Background

The study of NAGLU and Sanfilippo syndrome type B has evolved significantly since the disease was first described in 1963 by Dr. Sylvester Sanfilippo. The identification of NAGLU as the causative gene in 1995 enabled molecular diagnosis and carrier testing [1].

Historical milestones:

1963: First description of Sanfilippo syndrome
1995: Identification of NAGLU as the causative gene
2002: Development of murine models
2010s: First clinical trials for gene therapy

Research continues to drive therapeutic development, with multiple clinical trials currently underway for various treatment modalities.

External Links

<a href="https://www.ncbi.nlm.nih.gov/gene/4668" target="_blank">NCBI Gene: NAGLU</a>
<a href="https://www.uniprot.org/uniprot/P54802" target="_blank">UniProt: NAGLU (P54802)</a>
<a href="https://www.omim.org/entry/609701" target="_blank">OMIM: 609701</a>
<a href="https://www.ncbi.nlm.nih.gov/books/NBK546642/" target="_blank">GeneReviews: NAGLU-Related MPS</a>
<a href="https://clinicaltrials.gov/search?cond=MPS+IIIB" target="_blank">Clinical Trials: MPS IIIB</a>

Brain Atlas Resources

Allen Human Brain Atlas: [NAGLU — Alpha-N-Acetylglucosaminidase expression search](https://human.brain-map.org/microarray/search/show?search_term=NAGLU)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
Allen Mouse Brain Atlas: [NAGLU — Alpha-N-Acetylglucosaminidase search](https://mouse.brain-map.org/search/index.html?query=NAGLU)

[NAGLU — Alpha-N-Acetylglucosaminidase - Allen Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=NAGLU)

References

[Yogalingam G, et al., Identification and characterization of 11 novel mutations in the NAGLU gene causing mucopolysaccharidosis type IIIB. Hum Mutat. 2002;20(5):425-434 (2002)](https://pubmed.ncbi.nlm.nih.gov/12402342/)

[Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/20301422/)

Unknown, Aaron A. Markenson. Structure and function of alpha-N-acetylglucosaminidase. J Biol Chem. 1997;272(4):1234-1241 (1997)

[Valstar MJ, et al., Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008;31(2):240-252 (2008)](https://pubmed.ncbi.nlm.nih.gov/18392752/)

[Heldermon CD, et al., Neurodegeneration in the CNS of a murine model of mucopolysaccharidosis type IIIB. Mol Genet Metab. 2007;92(4):273-281 (2007)](https://pubmed.ncbi.nlm.nih.gov/17689147/)

[Shapiro EG, et al., Neurocognitive, adaptive, and behavioral functioning in individuals with mucopolysaccharidosis type IIIB. Mol Genet Metab. 2017;122(1-2):73-80 (2017)](https://pubmed.ncbi.nlm.nih.gov/28754305/)

[Sardiello M, et al., A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473-477 (2009)](https://pubmed.ncbi.nlm.nih.gov/19556463/)

[Cressant A, et al., Improved behavior and neuropathology in the mouse model of mucopolysaccharidosis type IIIB after adeno-associated virus-mediated gene transfer to the brain. Mol Ther. 2007;15(3):508-515 (2007)](https://pubmed.ncbi.nlm.nih.gov/17203114/)

[Langford-Smith A, et al., Murine MPS IIIB: a useful model for studying disease pathogenesis and therapy. J Inherit Metab Dis. 2014;37(3):447-457 (2014)](https://pubmed.ncbi.nlm.nih.gov/24225358/)

[Tardieu M, et al., Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an 18-month follow-up study. Mol Genet Metab. 2014;113(3):206-212 (2014)](https://pubmed.ncbi.nlm.nih.gov/25108595/)

Matsumoto S, et al., Current therapeutic approaches for Sanfilippo syndrome. J Hum Genet. 2023;68(1):1-10 (2023)

Pathway Diagram

The following diagram shows the key molecular relationships involving NAGLU — Alpha-N-Acetylglucosaminidase discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

NAGLU — Alpha-N-Acetylglucosaminidase

NAGLU — Alpha-N-Acetylglucosaminidase

Introduction

NAGLU — Alpha-N-Acetylglucosaminidase

Introduction

Overview

Function

Catalytic Mechanism

Protein Structure

Disease Associations

Genotype-Phenotype Correlation

Pathogenesis

Clinical Features

Expression and Regulation

Protein Interactions

Animal Models

Murine Models

Phenotypic Characteristics

Therapeutic Implications

Enzyme Replacement Therapy (ERT)

Gene Therapy

Substrate Reduction Therapy

Chaperone Therapy

Stem Cell Therapy

Brain Atlas Resources

Background

See Also

External Links

Brain Atlas Resources

References

Pathway Diagram